Xenon Pharmaceuticals (XENE) Share-based Compensation (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Share-based Compensation data on file, last reported at $16.9 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $16.9 million, up 38.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $58.4 million (up 9.23% YoY), and the FY2025 annual result was $53.7 million, up 5.9% from the prior year.
• Share-based Compensation rose to $16.9 million in Q1 2026 per XENE's latest filing, from $14.1 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $16.9 million in Q1 2026 and troughed at $3.6 million in Q1 2022.
• A 5-year average of $10.2 million and a median of $9.4 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 117.25% in 2022, then dropped 6.82% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $5.8 million in 2022, then soared by 57.98% to $9.2 million in 2023, then soared by 48.1% to $13.6 million in 2024, then increased by 3.79% to $14.1 million in 2025, then increased by 19.69% to $16.9 million in 2026.
• Business Quant data shows XENE's Share-based Compensation at $16.9 million in Q1 2026, $14.1 million in Q4 2025, and $13.7 million in Q3 2025.